Whatever has transpired in the last few weeks with the 'resignation' of Howell and the discontinuation of Yarra's involvement is due to a shift in strategy and I believe their realization
that they need to partner with a bigger company to advance their technologies. Howell and Yarra were roadblocks to moving in this new direction. I view this as positive and hope that the hiring of a media firm will also mean releases of over-due insight into the company and their products.
Look what ARNA did with a major pharma Eisai - $65,000,000 milestone payment when the DEA does a final sign-off on their Class IV designation. Eisai is picking up all marketing costs for the promotion of their drug Belviq for launch in the America's, per the contract. ARNA receives 32% of the profits for this agreement. They have also just signed an agreement for S. Korea with Ildong Pharma and received $5,000,000 milestone payment. They are now talking with potential European
partners and the payments could reach $100M+ for those rights. ARNA is about to bubble over with positive news. Already FDA approved. ARYC needs to execute with the same strategy and this stock would fly with the right partners. Rene and Mark, get your egos out of the way . . . please.